Aubrey Rankin - 15 Mar 2022 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
Director
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Mar 2022
Net transactions value
-$21,664
Form type
4
Filing time
17 Mar 2022, 17:50:59 UTC
Previous filing
06 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Tax liability $21,664 -1,372 -1.4% $15.79 94,091 15 Mar 2022 Direct F1
holding RVNC Common Stock 154,302 15 Mar 2022 The Rankin Irrevocable Trust F2
holding RVNC Common Stock 321,611 15 Mar 2022 Aubrey and Luanne Rankin Revocable Living Trust Dated July 1, 2009 F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 11,905 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Rankin's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
F2 These shares are held by The Rankin Irrevocable Trust. Mr. Rankin is a Trustee of the Rankin Irrevocable Trust.
F3 These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.